{"corpus_id":1526461,"paper_sha":"ea93b86cee267d9140d829c6764fd417e611cd8b","doi":"10.2174/1745017901713010092","arxiv_id":null,"pmid":29081826,"pmcid":"5633702","mag_id":2735853844,"dblp_id":null,"acl_id":null,"title":"Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy","year":2017,"publication_date":"2017-08-11","venue":"Clinical Practice and Epidemiology in Mental Health","journal":{"name":"Clinical Practice and Epidemiology in Mental Health : CP & EMH","pages":"92 - 103","volume":"13"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":49,"citation_count":25,"influential_citation_count":4,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://clinical-practice-and-epidemiology-in-mental-health.com/VOLUME/13/PAGE/92/PDF/","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/ea93b86cee267d9140d829c6764fd417e611cd8b","s2_open_access_license":"CCBY","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Background: This study investigates the antipsychotic use patterns of patients with schizophrenia and its correlations in their daily drug use patterns. Methods: Patients with schizophrenia who have regular records at two different community counselling centres (CCS) were included in the study. Information about their medications and sociodemographic data was recorded through face-to-face interviews and supporting information about their drug use patterns was obtained from their relatives/caregivers/nurse. The Clinical Global Impression Scale (severity of illness) and the General Assessment of Functionality scales were also administered. Results: Patients with schizophrenia used 2.0 ± 0.81 antipsychotics daily and 3.52 ± 2.55 pills (1–18). Seventy-one percent of the patients used two or more kinds of psychotropic drugs. The most frequently used antipsychotics were quetiapine, a second generation antipsychotic, and haloperidol, a typical antipsychotic. Clinical severity, regular visits to a CCS and use of depot antipsychotics were independent predictors for polypharmacy. Conclusion: The rate of polypharmacy use is high in Turkey. There are multiple risk factors related with polipharmacy. New studies should focus risk factors for preventing polypharmacy.","claims":[{"public_id":"cl_df32a4a0c59d238a7e3120ca4ff11a13","status":"active","text":"Clinical severity, regular visits to a community counselling centre, and use of depot antipsychotics were independent predictors of polypharmacy.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_df32a4a0c59d238a7e3120ca4ff11a13"},{"public_id":"cl_b8a5425462bb4247c36b98cb3e1634b4","status":"active","text":"Patients with schizophrenia used an average of 2.0 ± 0.81 antipsychotics daily and 3.52 ± 2.55 pills per day.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_b8a5425462bb4247c36b98cb3e1634b4"},{"public_id":"cl_d6d5421213e34280f83a32845fe679e4","status":"active","text":"Quetiapine and haloperidol were the most frequently used antipsychotics.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d6d5421213e34280f83a32845fe679e4"},{"public_id":"cl_be07c0acbd124f66e2c21e1a528199c5","status":"active","text":"Seventy-one percent of patients used two or more kinds of psychotropic drugs.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_be07c0acbd124f66e2c21e1a528199c5"},{"public_id":"cl_9ce33cfd141b409919574f673d763f7b","status":"active","text":"The rate of polypharmacy use is high in Turkey.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_9ce33cfd141b409919574f673d763f7b"}],"concepts":[{"public_id":"co_2704badf904aaa514f82df5ec5391c2e","status":"active","name":"polypharmacy","description":"Use of multiple medications concurrently, here referring to multiple psychotropic drugs or antipsychotics.","types":["clinical phenomenon"],"aliases":["polypharmacy use"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2704badf904aaa514f82df5ec5391c2e"},{"public_id":"co_449a5c1591cb0ac765e222735f0fdddf","status":"active","name":"Turkey","description":"The country in which the outpatient sample and polypharmacy rate were reported.","types":["geographic location"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_449a5c1591cb0ac765e222735f0fdddf"},{"public_id":"co_6830d6ba58feec0707d21b7cb884f064","status":"active","name":"Clinical Global Impression Scale","description":"A clinician-rated scale for assessing illness severity.","types":["measurement scale"],"aliases":["CGI"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6830d6ba58feec0707d21b7cb884f064"},{"public_id":"co_6dc30607dfdb4178cd4a690a8db0b516","status":"active","name":"depot antipsychotics","description":"Long-acting injectable antipsychotic medications.","types":["drug class"],"aliases":["long-acting injectable antipsychotics"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6dc30607dfdb4178cd4a690a8db0b516"},{"public_id":"co_8169c395d8ce32e2a201da3ae55a427b","status":"active","name":"quetiapine","description":"A second-generation antipsychotic medication used in the patient group.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8169c395d8ce32e2a201da3ae55a427b"},{"public_id":"co_acc1770591bce53f8453206d891a4f2a","status":"active","name":"psychotropic drugs","description":"Medications that act on the central nervous system and are used to treat psychiatric conditions.","types":["drug class"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_acc1770591bce53f8453206d891a4f2a"},{"public_id":"co_b0fa4df2ee5f60ce3c379a1c0a595af4","status":"active","name":"haloperidol","description":"A typical antipsychotic medication used in the patient group.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b0fa4df2ee5f60ce3c379a1c0a595af4"},{"public_id":"co_ca74d2a2cc76e474183e0ed718228f08","status":"active","name":"antipsychotic use patterns","description":"Patterns of daily antipsychotic medication use among the studied patients.","types":["clinical pattern"],"aliases":["antipsychotic use"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ca74d2a2cc76e474183e0ed718228f08"},{"public_id":"co_d6777998dd5a92de20358008e82977e4","status":"active","name":"schizophrenia outpatients","description":"Patients with schizophrenia receiving outpatient care in community counselling centres.","types":["patient group"],"aliases":["patients with schizophrenia"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d6777998dd5a92de20358008e82977e4"},{"public_id":"co_fed803d6f36a14ca49c4fbd35ce38a3a","status":"active","name":"community counselling centre","description":"A community-based center where the patients had regular records and visits.","types":["care setting"],"aliases":["CCS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fed803d6f36a14ca49c4fbd35ce38a3a"}],"external_ids":{"DOI":"10.2174/1745017901713010092","ArXiv":null,"PubMed":29081826,"PubMedCentral":"5633702","MAG":2735853844,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://clinical-practice-and-epidemiology-in-mental-health.com/VOLUME/13/PAGE/92/PDF/","landing_url":"https://www.semanticscholar.org/paper/ea93b86cee267d9140d829c6764fd417e611cd8b","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632032,"paper_uid":"312559e1-21cc-4de2-90ee-50aae27eba57","canonical_identity":{"paper_id":632032,"paper_uid":"312559e1-21cc-4de2-90ee-50aae27eba57","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/1526461"}